Download MendeleyNovel Hydroxyl Tricyclics (E.G., Gsk966587) as Potent Inhibitors of Bacterial Type Iia Topoisomerases.
Miles, T.J., Hennessy, A.J., Bax, B., Brooks, G., Brown, B.S., Brown, P., Cailleau, N., Chen, D., Dabbs, S., Davies, D.T., Esken, J.M., Giordano, I., Hoover, J.L., Huang, J., Jones, G.E., Kusalakumari Sukmar, S.K., Spitzfaden, C., Markwell, R.E., Minthorn, E.A., Rittenhouse, S., Gwynn, M.N., Pearson, N.D.(2013) Bioorg Med Chem Lett 23: 5437
- PubMed: 23968823
- DOI: https://doi.org/10.1016/j.bmcl.2013.07.013
- Primary Citation of Related Structures:
4BUL - PubMed Abstract:
During the course of our research to find novel mode of action antibacterials, we discovered a series of hydroxyl tricyclic compounds that showed good potency against Gram-positive and Gram-negative pathogens. These compounds inhibit bacterial type IIA topoisomerases. Herein we will discuss structure-activity relationships in this series and report advanced studies on compound 1 (GSK966587) which demonstrates good PK and in vivo efficacy properties. X-ray crystallographic studies were used to provide insight into the structural basis for the difference in antibacterial potency between enantiomers.
Organizational Affiliation:
Diseases of the Developing World CEDD, GlaxoSmithKline, Madrid, Spain. tim.j.miles@gsk.com
